drugset
drugset / Trial / NCT05139121

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

NCT05139121 ↗

Phase 3 Completed 1319 enrolled Mylan Technologies Inc. Mylan · collab
NaSingle-groupOpen-labelPrevention

Summary

Study of the contraceptive efficacy, cycle control, safety, and tolerability of MR-100A-01 in approxmiately 1200 women for up to 13 cycles

Timeline

Start
2021-10-26
Primary completion
2025-01-15
Completion
2025-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ethinyl estradiol Small molecule 0.264 mg Other
Subject norelgestromin Unknown 4.86 mg Other

Indications

No indication recorded.